GSA Capital Partners’s GenMark Diagnostics, Inc GNMK Stock Holding History

GSA Capital Partners’s Portfolio GNMK Stock Details GNMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-24,578	Closed	-$359K	–	1655
2020 Q4	$359K	Buy	+24,578	New	+$326K	0.06%	641
2020 Q2	–	Sell	-13,452	Closed	-$55K	–	1309
2020 Q1	$55K	Buy	+13,452	New	+$63.1K	0.01%	954
2019 Q4	–	Sell	-14,632	Closed	-$89K	–	1858
2019 Q3	$89K	Buy	+14,632	New	+$91.3K	0.01%	1283
2018 Q3	–	Sell	-14,196	Closed	-$91K	–	2018
2018 Q2	$91K	Buy	+14,196	New	+$93.8K	﹤0.01%	1599
2017 Q2	–	Sell	-35,290	Closed	-$452K	–	2058
2017 Q1	$452K	Buy	+35,290	New	+$425K	0.02%	1156

Other funds holding GNMK

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GSA Capital Partners's GNMK Position: Q1 2021 in Review

GSA Capital Partners sold out of GenMark Diagnostics, Inc (GNMK) in Q1 2021, closing a stake of 24,578 shares — an estimated $359K sold.

GSA Capital Partners first reported a position in GNMK in Q1 2017 and held it in 5 quarters. The position peaked at $452K in Q1 2017. 164 funds tracked by Wall St. Rank hold GNMK as of Q1 2021.

GSA Capital Partners reported no remaining GenMark Diagnostics, Inc position as of Q1 2021 after selling out during the quarter.
GSA Capital Partners sold 24,578 GenMark Diagnostics, Inc shares in Q1 2021, an estimated $359K.
GSA Capital Partners first reported a position in GenMark Diagnostics, Inc in Q1 2017 and held it in 5 quarters.
GSA Capital Partners's GenMark Diagnostics, Inc position peaked at $452K in Q1 2017.
164 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q1 2021.

Based on GSA Capital Partners's 13F filing for Q1 2021, filed 10 May 2021.